Skip to main content

Florbetapir F 18 Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Oct 4, 2021.

Florbetapir F 18 is also known as: Amyvid

Florbetapir F 18 Pregnancy Warnings

Animal reproduction studies have not been conducted. There are no controlled data in human pregnancy. All radiopharmaceuticals, including Florbetapir F-18, can potentially cause fetal harm. The likelihood of fetal harm depends on the stage of fetal development and the radiopharmaceutical dose. Pregnancy status should be assessed before administering this drug to a female of childbearing potential.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if clearly needed.

US FDA pregnancy category: C

See references

Florbetapir F 18 Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

If breastfeeding is discontinued, the patient should pump and discard her breast milk and use alternate infant nutrition sources (e.g., stored breast milk or infant formula) for 24 hours after administration of the drug.

See references

References for pregnancy information

  1. Product Information. Amyvid (florbetapir F-18). Lilly, Eli and Company. 2022.

References for breastfeeding information

  1. Product Information. Amyvid (florbetapir F-18). Lilly, Eli and Company. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.